High-intensity therapy: rationale, indications and safety issues. Prospects of rosuvastatin in clinical practice


Cite item

Full Text

Abstract

The review is devoted to the problem of high-intensity therapy. Evidence of the effectiveness of statin prescribing in high-intensity mode is presented to patients with very high cardiovascular risk. Indications for such therapy and its principles are indicated. The issues of tolerability and safety of high-intensity therapy are considered.

About the authors

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: bubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Townsend N, Wilson L, Bhatnagar P. et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37: 3232-45. doi: 10.1093/eurheartj/ehw334
  2. Piepoli M.F, Hoes A.W, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-81.
  3. World Health Organisation. WHO Global Health Repository. Cardiovascular diseases, deaths per 100 000. 2016. Data by country. http://apps.who.int/gho/data/node.main. A865CARDIOVASCULAR?lang=en
  4. Keys A, Menotti A, Aravanis C. et al. Seven Countries Study. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13 (2): 141-54.
  5. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016; 19 (1): 15-23
  6. Мешков А.Н., Ершова А.И., Деев А.Д. и др. от имени участников исследования ЭССЕ-РФ. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012-2014 гг. Кардиоваскулярная терапия и профилактика. 2017; 4: 62-7.
  7. Ference B.A, Ginsberg H.N, Graham I. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. doi: 10.1093/eurheartj/ehx144
  8. Jacobson T.A, Ito M.K, Maki K.C. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 - Full Report. J Clin Lipidol 2015; 9: 129-69.
  9. Catapano A.L, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37: 2999-3058. doi: 10.1093/eurheartj/ ehw272
  10. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр. Атеросклероз и дислипидемии. 2017; 3 (28): 5-22.
  11. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
  12. Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61.
  13. Karlson B.W, Wiklund O, Palmer M.K. et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J - Cardiovasc Pharmacother 2016; 2: 212-7.
  14. Pitt B, Loscalzo J, Monyak J.et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol 2012; 109: 1239-46.
  15. Schwartz G.G, Olsson A., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
  16. Cannon C.P, Braunwald E, McCabe C.H et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004; 350: 1495-504.
  17. Wiviott S.D, Cannon C.P, Morrow D.A et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46: 1411-6.
  18. Boekholdt S.M, Hovingh G.K, Mora S. et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials. JACC 2014; 5: 485-94.
  19. Sabatine M.S, Giugliano R.P, Keech A.C et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-22. doi: 10.1056/NEJMoa1615664
  20. Ridker P.M, Danielson E, Fonseca E.A.H. et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men women with elevated C-Reactive Protein. N Engl J Med 2008; 359: 2195-207.
  21. Ridker P.M, Mora S, Rose L, on Behalf of the JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016; 37: 1373-9. doi: 10.1093/eurheartj/ehw046
  22. Hsia J, MacFadyen J.G, Monyak J, Ridker P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol №50 mg/dl with rosuvastatin The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57: 1666-75. doi: 10.1016/j.jacc.2010. 09.082
  23. Nicholls S.J, Ballantyne C.M, Barter P.J. et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87.
  24. Nissen S.E, Tuzcu E.M, Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80.
  25. Kataoka Y, Hammadah M, Puri R. et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis 2015; 242: 490-5.
  26. Falk E, Nakano M, Bentzon J.F. et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013; 34: 719-28.
  27. Virmani R, Kolodgie F.D, Burke A.P.et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
  28. Puri R, Nissen S.E, Libby P. et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013; 128: 2395-403.
  29. Crouse III J.R, Raichlen J.S., Evans G.W. et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53.
  30. Jones P.H, Hunninghake D.B, Ferdinand K.C. et al., for the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) Study Group. Effects of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin on Non-High-Density Lipoprotein Cholesterol, Apolipoproteins, and Lipid Ratios in Patients with Hypercholesterolemia: Additional Results from the STELLAR Trial. Clin Ther 2004; 26: 1388-99.
  31. Nicholls S.J, Puri R, Anderson T.et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84.
  32. Ference B.A, Yoo W, Alesh I. et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631-9.
  33. Vallejo-Vaz A.J, Robertson M, Catapano A.L. et al. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up. Circulation 2017; 136: 1876-91.
  34. Ference B. A naturally randomized trial comparing the effect of long-term exposure to LDL-C, lower SBP, or both on the risk of cardiovascular disease. European Society of Cardiology Congress 2016; August 29, 2016; Rome, Italy. Abstract 3163.
  35. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90. doi: 10.1016/S0140-6736(07)60716-8
  36. McGuinnes B, O’Hare J, Craig D et al. Cochrane review on 'Statins for the treatment of dementia'. Int J Geriatr Psychiatry 2013; 28 (2): 119-26.
  37. McKinney J.S, Kostis W.J. Statin therapy and the risk of intracerebral hemorrhage: a metaanalysis of 31 randomized controlled trials. Stroke 2012; 43 (8): 2149-56.
  38. White C.M. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-70.
  39. Cheng W.M. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26: 1368-87.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies